




The relative strengths and weaknesses of GW Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GW Pharmaceuticals PLC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 98% points. The greatest weakness of GW Pharmaceuticals PLC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 313%, being 63% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	390,711
Cost of Goods Sold	5,986
Intangible Assets	6,959
Liabilities, Current	58,669
Liabilities, Non-Current	16,707
Other Assets	10,484
Other Compr. Net Income	-676
Other Expenses	5,046
Other Liabilities	0
Other Net Income	-1,318
Other Revenues	12,737
Property and Equipment	82,381
Research and Development	153,736
Selling, General and Administrative Expense	141,818

Output Variable	Value in 1000 USD
Assets	490,535
Liabilities	75,376
Expenses	306,586
Revenues	12,737
Stockholders Equity	415,159
Net Income	-295,167
Comprehensive Net Income	-295,505
BaseVar	443,614
ECR before LimitedLiability	215%
Economic Capital Ratio	313%